


CLAIMS

1. A process for producing a compound of the following formula (I):




(I)

5


which process comprises:

- (a) treating a compound of the following formula (5):



(5)


with a compound of the following formula (6):




(6)

10

to generate an intermediate compound of the following formula (7):




(b) treating a compound of formula (7) as defined above with a compound of the following formula (8):



(c) recovering a compound of formula (I) as defined above.

2. A process according to claim 1, wherein step (a) is conducted in the presence of tetrakis(triphenylphosphine)palladium and potassium carbonate in 1,4-dioxane and water.
3. A process according to claim 1 or 2 wherein step (b) is conducted in dichloromethane in the presence of pyridine and Cu(OAc)₂·H₂O.
4. A process according to any one of claims 1 to 3 which further comprises, prior to step (b), purifying and recrystallizing the intermediate compound of formula (7).
5. A process according to claim 4 wherein the compound of formula (7) is purified by passage through a silica plug.
6. A process according to claim 4 or 5 wherein the compound of formula (7) is recrystallized from ethyl acetate.


7. A process according to any one of the preceding claims which further comprises producing the compound of formula (5) by treating a compound of the following formula (4):




5 with acetic acid.

8. A process according to claim 7, wherein the reaction between the compound of formula (4) and acetic acid is conducted at a temperature of from 40° – 50°C.

10 9. A process according to claim 7 or 8, wherein the compound of formula (4) is generated by treating a compound of the following formula (3)



with a compound of the following formula (9):




15

and 1-propylphosphonic acid cyclic anhydride (T₃P®) in dichloromethane, in the presence of *N,N*-diisopropylethylamine.


10. A process according to any one of the preceding claims, which further comprises recrystallizing the compound of formula (I) from ethyl acetate:n-heptane and recovering the recrystallized product.

5 11. A process according to any one of the preceding claims, which further comprises formulating the resulting compound of formula (I) with one or more pharmaceutically acceptable carriers or diluents to produce a pharmaceutical composition.

10 12. A compound which is of the following formula (I'):



13. A compound of the following formula (I) in crystal form:



15 wherein the crystal form is characterised by the data shown in the XRPD diffractogram of Figure 1 and/or by the single crystal X-ray structure of Figure 2.

14. A pharmaceutical composition comprising a compound as defined in claim 12 or 13 and one or more pharmaceutically acceptable carriers or diluents.